Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Female Ductal Carcinoma In Situ Clear all
Terminated Not applicable Interventional

Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy

NCT02023008
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Fatigue, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
yoga therapy, internet-based intervention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

NCT00769379
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation
Other · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1249
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 764 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 24, 2026, 3:09 AM EDT
Completed No phase listed Observational

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

NCT00373191
View directory record Official record
Conditions
Breast Cancer
Interventions
chemotherapy, endocrine therapy, DNA methylation analysis, protein analysis, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

NCT00952731
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Interventions
oral placebo, afimoxifene, tamoxifen citrate, placebo gel
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Not applicable Interventional

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

NCT00103181
View directory record Official record
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation, MammoSite or other single-entry intracavitary device
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
374
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 295 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jul 24, 2026, 3:09 AM EDT
Terminated Phase 2 Interventional Results available

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

NCT02540330
View directory record Official record
Conditions
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
Interventions
Fulvestrant
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 24, 2026, 3:09 AM EDT
Terminated Phase 2 Interventional

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

NCT00082667
View directory record Official record
Conditions
Breast Cancer
Interventions
gefitinib, Surgery
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 24, 2026, 3:09 AM EDT
Completed No phase listed Observational

Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast

NCT00665782
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions
laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care, therapeutic conventional surgery
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 1 Interventional

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

NCT00005886
View directory record Official record
Conditions
Breast Cancer
Interventions
arzoxifene hydrochloride, tamoxifen citrate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Not applicable Interventional

Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy

NCT03430765
View directory record Official record
Conditions
Persistent Postsurgical Pain, Breast Cancer Female, Ductal Carcinoma in Situ
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Katherine Hadlandsmyth
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Jul 24, 2026, 3:09 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer

NCT00334542
View directory record Official record
Conditions
Breast Cancer
Interventions
simvastatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Not applicable Interventional Results available

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

NCT00555152
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, HER2/Neu Positive
Interventions
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

NCT00244959
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jul 24, 2026, 3:09 AM EDT
Completed No phase listed Observational

Abbreviated Breast MRI After Cancer Treatment

NCT03664778
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 82 Years · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 24, 2026, 3:09 AM EDT
Completed No phase listed Observational

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

NCT00569543
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Hot Flushes
Interventions
soy protein, isoflavones, Tamoxifen, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
14
States / cities
Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 24, 2026, 3:09 AM EDT
Terminated Not applicable Interventional

Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

NCT00794989
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
Ground Flaxseed, No Intervention
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 3 Interventional

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

NCT00262899
View directory record Official record
Conditions
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
counseling intervention, educational intervention, psychosocial assessment and care
Behavioral · Other · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chevy Chase, Maryland • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers

NCT01043003
View directory record Official record
Conditions
Breast Cancer, Ductal Breast Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
educational intervention, quality-of-life assessment, Questionnaire Administration, psychosocial support for caregiver, assessment of therapy complications, informational intervention
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 24, 2026, 3:09 AM EDT
Active, not recruiting Phase 2 Interventional

Metformin and Nightly Fasting in Women With Early Breast Cancer

NCT05023967
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jul 24, 2026, 3:09 AM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 24, 2026, 3:09 AM EDT